[go: up one dir, main page]

PE20060078A1 - Compuesto pirazolo [3,4-b]piridina como inhibidor de fosfodiesterasa tipo iv - Google Patents

Compuesto pirazolo [3,4-b]piridina como inhibidor de fosfodiesterasa tipo iv

Info

Publication number
PE20060078A1
PE20060078A1 PE2005000299A PE2005000299A PE20060078A1 PE 20060078 A1 PE20060078 A1 PE 20060078A1 PE 2005000299 A PE2005000299 A PE 2005000299A PE 2005000299 A PE2005000299 A PE 2005000299A PE 20060078 A1 PE20060078 A1 PE 20060078A1
Authority
PE
Peru
Prior art keywords
phosphodiesterase
inhibitor
type
pyrazolo
hydrochloride
Prior art date
Application number
PE2005000299A
Other languages
English (en)
Inventor
Iv Siegfried Benjamin Christensen
Caroline Mary Cook
Martin Redpath Johnson
Mika Kristian Lindvall
Naimisha Trivedi
Lionel Trottet
Amyn Pyarali Sayani
Paul Spencer Jones
Christopher David Edlin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0405893A external-priority patent/GB0405893D0/en
Priority claimed from GB0505214A external-priority patent/GB0505214D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20060078A1 publication Critical patent/PE20060078A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FORMADA POR COMBINACION DE 4-{[1-(AMINOCARBONIL)-4-PIPERIDINIL]AMINO}-N-[(3,4-DIMETILFENIL)METIL]-1-ETIL-1H-PIRAZOLO[3,4-b]PIRIDIN-5-CARBOXAMIDA Y UNA SAL DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLE QUE TIENE UN pKa DE 1,5 O MENOR. DICHA SAL ES SELECCIONADO ENTRE BROMHIDRATO, CLORHIDRATO, SULFATO, NITRATO, FOSFATO, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHA COMPOSICION ES INHIBIDOR DE FOSFODIESTERASA TIPO IV, SIENDO UTILES EN EL TRATAMIENTO DE DERMATITIS ATOPICA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA, ASMA, ARTRITIS REUMATOIDE , ENTRE OTROS
PE2005000299A 2004-03-16 2005-03-16 Compuesto pirazolo [3,4-b]piridina como inhibidor de fosfodiesterasa tipo iv PE20060078A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0405893A GB0405893D0 (en) 2004-03-16 2004-03-16 Compounds
GB0505214A GB0505214D0 (en) 2005-03-14 2005-03-14 Compounds

Publications (1)

Publication Number Publication Date
PE20060078A1 true PE20060078A1 (es) 2006-03-10

Family

ID=34962723

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000299A PE20060078A1 (es) 2004-03-16 2005-03-16 Compuesto pirazolo [3,4-b]piridina como inhibidor de fosfodiesterasa tipo iv

Country Status (15)

Country Link
US (2) US7709497B2 (es)
EP (2) EP1735314A1 (es)
JP (2) JP2007529486A (es)
KR (1) KR20060130744A (es)
AR (1) AR048175A1 (es)
AU (1) AU2005223351A1 (es)
BR (1) BRPI0508843A (es)
CA (1) CA2559629A1 (es)
IL (1) IL178011A0 (es)
MA (1) MA28531B1 (es)
NO (1) NO20064450L (es)
PE (1) PE20060078A1 (es)
RU (1) RU2378274C2 (es)
TW (1) TW200602051A (es)
WO (2) WO2005090352A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
WO2007122165A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
TW200817006A (en) 2006-06-23 2008-04-16 Smithkline Beecham Corp IL-8 receptor antagonist
AU2007280214A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2249646A4 (en) * 2008-02-06 2013-09-25 Glaxo Group Ltd PDE4 muscarinic Antagonist-DOPPELPHARMACOPHOREN
TW200946526A (en) 2008-02-06 2009-11-16 Glaxo Group Ltd Dual pharmacophores-PDE4-muscarinic antagonistics
CL2009000250A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b]piridina carboxamida; composicion farmaceutica que los comprende; y su uso en el tratamiento del asma, epoc y rinitis.
AR070563A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Compuesto de un biciclo condensado pirazol-piridin-amina, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de enfermedades respiratorias.
GB0806900D0 (en) * 2008-04-16 2008-05-21 Dow Corning Fabric care emulsions
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
MX2011007499A (es) 2009-01-13 2011-08-04 Glaxo Group Ltd Derivados de pirimidin-carboxamida como inhibidores de la cinasa syk.
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
HRP20130149T1 (hr) * 2009-04-13 2013-03-31 Sulur Subramaniam Vanangamudi Medicinska krema s fusidinskom kiselinom proizvedena korištenjem natrijevog fusidata i koja sadrži biopolimer, te postupak za njenu proizvodnju
UA101098C2 (xx) 2009-04-30 2013-02-25 Глаксо Груп Лимитед Заміщені оксазолом індазоли як інгібітори pi3-кінази$замещенные оксазолом индазолы как ингибиторы pi3-киназы
EP2507226A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Novel compounds
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
EP2507223A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
ES2602972T3 (es) 2010-09-08 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Derivados de indazol para su uso en el tratamiento de infección por virus de la gripe
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EP2888603B1 (en) 2012-08-27 2016-10-12 Aktiebolaget Electrolux Robot positioning system
CN110710920B (zh) 2013-04-15 2021-12-14 伊莱克斯公司 具有伸出的侧刷的机器人真空吸尘器
CN105101854A (zh) 2013-04-15 2015-11-25 伊莱克斯公司 机器人真空吸尘器
US9011934B2 (en) 2013-06-14 2015-04-21 SatisPharma, LLC Multi-purpose anti-itch treatment
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
JP6687286B2 (ja) 2013-12-19 2020-04-22 アクチエボラゲット エレクトロルックス ロボット掃除機およびランドマーク認識方法
CN105829985B (zh) 2013-12-19 2020-04-07 伊莱克斯公司 具有周边记录功能的机器人清洁设备
EP3084539B1 (en) 2013-12-19 2019-02-20 Aktiebolaget Electrolux Prioritizing cleaning areas
WO2015090397A1 (en) 2013-12-19 2015-06-25 Aktiebolaget Electrolux Robotic cleaning device
KR102159206B1 (ko) 2013-12-19 2020-09-23 에이비 엘렉트로룩스 회전 사이드 브러시의 적응형 속도 제어
JP6494118B2 (ja) 2013-12-19 2019-04-03 アクチエボラゲット エレクトロルックス 障害物の乗り上げの検出に伴うロボット掃除機の制御方法、並びに、当該方法を有するロボット掃除機、プログラム、及びコンピュータ製品
JP6638988B2 (ja) 2013-12-19 2020-02-05 アクチエボラゲット エレクトロルックス サイドブラシを有し、渦巻きパターンで動くロボットバキュームクリーナ
WO2015090439A1 (en) 2013-12-20 2015-06-25 Aktiebolaget Electrolux Dust container
CR20160529A (es) 2014-05-12 2017-01-02 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmacéuticas para tratar enfermedades infecciosas
EP3167341B1 (en) 2014-07-10 2018-05-09 Aktiebolaget Electrolux Method for detecting a measurement error in a robotic cleaning device
US10499778B2 (en) 2014-09-08 2019-12-10 Aktiebolaget Electrolux Robotic vacuum cleaner
CN106659344B (zh) 2014-09-08 2019-10-25 伊莱克斯公司 机器人真空吸尘器
US9452178B1 (en) 2014-10-22 2016-09-27 SatisPharma, LLC Acne formulations, treatments, and pressure sensitive patches for delivery of acne formulations
WO2016091291A1 (en) 2014-12-10 2016-06-16 Aktiebolaget Electrolux Using laser sensor for floor type detection
WO2016091320A1 (en) 2014-12-12 2016-06-16 Aktiebolaget Electrolux Side brush and robotic cleaner
KR102326401B1 (ko) 2014-12-16 2021-11-16 에이비 엘렉트로룩스 로봇 청소 장치를 위한 청소 방법
EP3234714B1 (en) 2014-12-16 2021-05-12 Aktiebolaget Electrolux Experience-based roadmap for a robotic cleaning device
CN107405034B (zh) 2015-04-17 2022-09-13 伊莱克斯公司 机器人清洁设备以及控制所述机器人清洁设备的方法
KR102445064B1 (ko) 2015-09-03 2022-09-19 에이비 엘렉트로룩스 로봇 청소 장치의 시스템
KR20180083323A (ko) * 2015-10-09 2018-07-20 애브비 에스.에이.알.엘. N-설포닐화 피라졸로[3,4-b]피리딘-6-카복스아미드 및 사용 방법
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
KR102588486B1 (ko) 2016-03-15 2023-10-11 에이비 엘렉트로룩스 로봇 청소 장치 및 로봇 청소 장치에서의 절벽 검출 실시 방법
EP3454707B1 (en) 2016-05-11 2020-07-08 Aktiebolaget Electrolux Robotic cleaning device
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2018219473A1 (en) 2017-06-02 2018-12-06 Aktiebolaget Electrolux Method of detecting a difference in level of a surface in front of a robotic cleaning device
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN111093447B (zh) 2017-09-26 2022-09-02 伊莱克斯公司 机器人清洁设备的移动控制
KR102034538B1 (ko) * 2017-11-28 2019-10-21 주식회사한국파마 Jak 저해제 화합물, 및 이의 제조방법
CN111875594A (zh) * 2020-07-21 2020-11-03 中国药科大学 具有磷酸二酯酶4b抑制活性的吲唑杂环类化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787249A (fr) * 1971-08-05 1973-02-05 Squibb & Sons Inc Derives amino d'acides pyrazolopyridine carboxyliques, leurs esters et les sels de ces composes, ainsi que leurs procedes de preparation
US3925388A (en) * 1971-08-05 1975-12-09 Squibb & Sons Inc 4-Piperazino-{8 3,4-b{9 pyridine-5-carboxylic acids and esters
US3833594A (en) * 1971-08-05 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxylic acids and esters
US3856799A (en) * 1971-08-05 1974-12-24 Squibb & Sons Inc Intermediates for production of amino derivatives of pyrazolopyridine carboxylic acids and esters
CA1003419A (en) 1971-11-23 1977-01-11 Theodor Denzel Process for the production of pyrazolo (3,4-b) pyridines
US3979399A (en) * 1972-11-15 1976-09-07 E. R. Squibb & Sons, Inc. Amino derivatives of pyrazolopyridine carboxamides
US3840546A (en) * 1972-11-15 1974-10-08 Squibb & Sons Inc Amino derivatives of pyrazolopyridine carboxamides
US3833598A (en) * 1972-12-29 1974-09-03 Squibb & Sons Inc Amino derivatives of pyrazolopyridine-6-carboxylic acids and esters
US4115394A (en) 1974-05-06 1978-09-19 E. R. Squibb & Sons, Inc. Amino derivatives of 6-phenylpyrazolo[3,4-b]pyridines
US4364948A (en) 1981-09-28 1982-12-21 Ici Americas Inc. Pyrazolo[3,4-b]pyridine compounds
GB8425104D0 (en) 1984-10-04 1984-11-07 Ici America Inc Amide derivatives
US5547954A (en) * 1994-05-26 1996-08-20 Fmc Corporation 2,4-Diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides
US5593997A (en) * 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
RU2134498C1 (ru) * 1998-12-08 1999-08-10 Таран Александр Иванович Контактный узел
NZ517575A (en) 1999-09-30 2004-04-30 Neurogen Corp Certain alkylene diamine-substituted heterocycles
GB9929685D0 (en) 1999-12-15 2000-02-09 Merck Sharp & Dohme Therapeutic agents
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
US6670364B2 (en) 2001-01-31 2003-12-30 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
WO2002098878A1 (en) 2001-02-08 2002-12-12 Memory Pharmaceuticals Corporation Trifluoromethylpurines as phosphodiesterase 4 inhibitors
US6677365B2 (en) 2001-04-03 2004-01-13 Telik, Inc. Antagonists of MCP-1 function and methods of use thereof
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
FR2828693B1 (fr) * 2001-08-14 2004-06-18 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
GB0230045D0 (en) * 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004024728A2 (en) * 2002-09-16 2004-03-25 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
US7117650B2 (en) * 2002-12-09 2006-10-10 Forrest Dockery Hanger system
AU2004299277A1 (en) * 2003-12-19 2005-06-30 Glaxo Group Limited Pyrazolo (3,4-b) pyridine compounds, and their use as phosphodiesterase inhibitors
GB0405933D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds
EP1735314A1 (en) 2004-03-16 2006-12-27 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compound, and its use as a pde4 inhibitor
GB0405937D0 (en) 2004-03-16 2004-04-21 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
NO20064450L (no) 2006-11-14
RU2378274C2 (ru) 2010-01-10
EP1735314A1 (en) 2006-12-27
WO2005090352A1 (en) 2005-09-29
BRPI0508843A (pt) 2007-08-28
JP2007529486A (ja) 2007-10-25
AU2005223351A1 (en) 2005-09-29
KR20060130744A (ko) 2006-12-19
IL178011A0 (en) 2006-12-31
EP1740590A1 (en) 2007-01-10
WO2005090354A1 (en) 2005-09-29
US20070280971A1 (en) 2007-12-06
US20080275078A1 (en) 2008-11-06
JP2007529464A (ja) 2007-10-25
MA28531B1 (fr) 2007-04-03
US7709497B2 (en) 2010-05-04
CA2559629A1 (en) 2005-09-29
RU2006132684A (ru) 2008-04-27
TW200602051A (en) 2006-01-16
AR048175A1 (es) 2006-04-05

Similar Documents

Publication Publication Date Title
PE20060078A1 (es) Compuesto pirazolo [3,4-b]piridina como inhibidor de fosfodiesterasa tipo iv
NO20071988L (no) Kjemiske forbindelser
BR0009952A (pt) Composto, pró-droga, processo para produzir um composto, composição farmacêutica, método para antagonizar um receptor de adenosina a3, para inibir a p38 map quinase e a produção de tnf-alfa e para prevenir ou tratar doenças, e uso de um composto
BR0107964A (pt) Derivados de nicotinamida benzofundida com heterociclica úteis como inibidores seletivos de isozimas pde4
NO20074391L (no) CIS-2,4,5-triaryl-imidazoliner og deres anvendelse som anti-cancer medikamenter
WO2011064171A3 (de) Verfahren zur herstellung von methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
NO20064166L (no) Utvalgte CGRP-antagonister, deres fremstilling og deres anvendelse som medikanmenter
WO2004037811A8 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
DE602007009995D1 (de) Muteine von tearlipocalin und verfahren zu deren gewinnung
WO2007040438A3 (en) Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2005103050A3 (en) Azaindoles useful as inhibitors of rock and other protein kinases
WO2007122580A3 (en) Compositions of phenylephrine useful for treatment of respiratory illness
WO2008024497A3 (en) INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1
WO2009065919A3 (de) Organische verbindungen
WO2008023258A8 (en) Piperidine derivatives
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
ECSP055595A (es) Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2009065920A3 (de) Verbindungen
ATE554086T1 (de) Scopin-salze und deren verwendung in verfahren zur herstellung von n-demethyl-tiotropium und tiotropiumbromid
WO2011064156A3 (de) Verfahren zur herstellung von methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat und dessen aufreinigung für die verwendung als pharmazeutischer wirkstoff
TW200714586A (en) Crystalline forms of a biphenyl compound
WO2010091104A8 (en) Glucosylceramide synthase inhibitors
WO2008128009A3 (en) Aminopyrimidines useful as kinase inhibitors

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed